0001621221 2026-01-01 2026-06-30 0001621221 2026-08-11 shares 0001621221 true --12-31 Q2 2026 10-Q/A true 2026-06-30 false 001-38951 ARTELO BIOSCIENCES, INC. NV 33-1220924 505 Lomas Santa Fe Suite 160 Solana Beach CA US 92075 858 925-7049 Common Stock, $0.001 par value per share ARTL NASDAQ Yes Yes Non-accelerated Filer true false false 4595068 The purpose of this Amendment No. 1 (this “Amendment”) to the Quarterly Report on Form 10-Q of Artelo Biosciences, Inc. (the “Company”) for the period ended June 30, 2026 (the “Original Report”), as filed with the Securities and Exchange Commission (the “SEC”) on August 12, 2026, is solely to amend Part II “Item 1. Legal Proceedings” to include information regarding an arbitration claim that was inadvertently omitted from the Original Report. In addition, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended, new certifications of our principal executive officer and principal financial officer are filed as exhibits to this Amendment under Part II “Item 6. Exhibits”. Except as described above, this Amendment makes no other changes to the Original Report. This Amendment does not reflect subsequent events occurring after the original filing of the Original Report or modify or update in any way those disclosures that may be affected by subsequent events. Accordingly, this Amendment should be read in conjunction with the Original Report and our other filings with the SEC.